TY - JOUR T1 - The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer JF - Anticancer Research JO - Anticancer Res SP - 3619 LP - 3625 DO - 10.21873/anticanres.12636 VL - 38 IS - 6 AU - KATRIN KREIENBRING AU - ANNIKA FRANZ AU - ROLF RICHTER AU - DUSKA DRAGUN AU - HARALD HEIDECKE AU - DOMINIK MÜLLER AU - MONIKA MENTZE AU - RALF DECHEND AU - JALID SEHOULI AU - ELENA IOANA BRAICU Y1 - 2018/06/01 UR - http://ar.iiarjournals.org/content/38/6/3619.abstract N2 - Aim: This study aimed to analyze the predictive, prognostic and diagnostic value of autoantibodies to coagulation factor II thrombin receptor (F2R; protease-activated receptor 1, PAR1) (PAR1-AB) in patients with primary epithelial ovarian cancer (EOC). Materials and Methods: A total of 197 patients with primary EOC and 200 healthy female blood donors were included in the study. Enzyme-linked immunosorbent assay was applied to determine PAR1-AB levels in blood sera taken preoperatively. Correlation of PAR1-AB with clinicopathological outcome, progression-free (PFS) and overall (OS) survival was analyzed and patients were compared with controls. Results: PAR1-AB was significantly negatively correlated with histological grading (p=0.008) and was significantly lower in the patient group compared to healthy controls (p<0.001). There was no significant correlation of PAR1-AB level with PFS or OS. Conclusion: This study showed PAR1-AB to significantly decrease in patients with primary EOC and with histological high-grade carcinoma. The relevance of PAR1-AB in early detection of ovarian cancer and follow-up for EOC should be further investigated. ER -